Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2011; 17(4): 506-513
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506
Evaluation of Cladribine treatment in refractory celiac disease type II
Greetje J Tack, Wieke HM Verbeek, Department of Gastroenterology and Hepatology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Abdul Al-Toma, Department of Gastroenterology and Hepatology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
Dirk J Kuik, Department of Epidemiology and Biostatistics, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Marco WJ Schreurs, Department of Pathology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Otto Visser, Department of Haematology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Chris JJ Mulder, Department of Gastroenterology and Hepatology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
Author contributions: Tack GJ, Al-Toma A and Mulder CJJ designed the research; Tack GJ and Verbeek WHM performed the research; Kuik DJ contributed statistical analytic tools; Tack GJ and Verbeek WHM analyzed the data and wrote the paper; Mulder CJJ, Visser O and Schreurs MWJ drafted the article and revised it critically for important intellectual content.
Supported by An Unrestricted Grant from Astra Zeneca
Correspondence to: Greetje J Tack, MD, Department of Gastroenterology and Hepatology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. g.tack@vumc.nl
Telephone: +31-20-4440613 Fax: +31-20-4440554
Received: June 8, 2010
Revised: September 27, 2010
Accepted: October 3, 2010
Published online: January 28, 2011
Revised: September 27, 2010
Accepted: October 3, 2010
Published online: January 28, 2011
Core Tip